Clinical Trials

As of January 25, 2018, the NIH, the biggest funder of biomedical research in the world, is implementing policy changes which will affect the majority of US laboratories working with human subjects.

We think it is vital for all parties, external stakeholders and the public to engage in an  informed, productive debate about these developments to identify issues and opportunities. In this special collection of commissioned opinion pieces, representatives of international funding agencies and science regulators, non-profit organizations and think tanks, and leading basic and clinical researchers in the US and Europe contribute novel, thought-provoking arguments. In an accompanying Q&A, Michael Lauer of the NIH addresses questions regarding the implementation and gives advice on future grant applications